Compare Mercadolibre Inc (MELI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Novartis AG — how do they compare? Mercadolibre Inc trades at $1,817 (market cap $92.90B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 3.1× Mercadolibre Inc's market cap, and Novartis AG pays a 3.17% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| MELI | NVS | |
|---|---|---|
Market Cap | $92.90B | $290.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.51K | $168.62 |
52-Week Low | $1.55K | $113.50 |
Enterprise Value | $99.79B | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,822.65, up 0.48% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal overall, with key resistance near $1,833, while recent earnings have missed expectations for three consecutive quarters. Revenue growth remains robust, reaching $28.89 billion in 2025, though net income margins have moderated. Analyst sentiment is strongly positive with a $2,220 consensus price target, but institutional selling and an ongoing legal investigation present near-term headwinds.
The outlook for MELI balances strong long-term growth potential in Latin American e-commerce and fintech against near-term margin pressure and execution risks. Investment appeal hinges on the company's ability to translate top-line expansion into sustained profitability, while key risks include competitive intensity, credit quality concerns, and macroeconomic volatility in core markets.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
